Dinwoodie W R, Bartolucci A A, Lyman G H, Velez-Garcia E, Martelo O J, Sarma P R
Cancer Treat Rep. 1986 Feb;70(2):267-70.
Adults with advanced, measurable, squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, bleomycin, and vindesine. Of 27 evaluable patients, seven (29%) had partial response, all occurring within the first two cycles of therapy. Of 13 patients receiving more than two cycles, only five completed the five planned cycles of therapy and did not progress while receiving the additional three cycles. Granulocytopenia was the major toxic effect observed, with 52% of the patients having neutrophil counts less than 1000/mm3. Findings suspicious for bleomycin pulmonary toxicity were observed in two evaluable patients and bleomycin toxicity was pathologically confirmed in one ineligible patient. Based on the results of this study, this regimen cannot be recommended for routine use in patients with advanced esophageal cancer. The search for more effective and less toxic regimens should continue.
患有晚期、可测量的食管鳞状细胞癌的成年患者接受了顺铂、博来霉素和长春地辛联合治疗。在27例可评估患者中，7例（29%）出现部分缓解，均发生在治疗的前两个周期内。在13例接受两个以上周期治疗的患者中，只有5例完成了计划的五个周期治疗，并且在接受额外三个周期治疗时未进展。观察到的主要毒性作用是粒细胞减少，52%的患者中性粒细胞计数低于1000/mm3。在2例可评估患者中观察到疑似博来霉素肺毒性的表现，在1例不符合条件的患者中病理证实为博来霉素毒性。基于本研究结果，该方案不推荐用于晚期食管癌患者的常规治疗。应继续寻找更有效且毒性更小的治疗方案。
